Conflict of interest: None to declare.
Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study
Article first published online: 22 FEB 2013
© 2013 The International Society of Dermatology
International Journal of Dermatology
Volume 52, Issue 9, pages 1081–1087, September 2013
How to Cite
Jacobi, A., Kupke, C., Behzad, M. and Hertl, M. (2013), Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. International Journal of Dermatology, 52: 1081–1087. doi: 10.1111/j.1365-4632.2012.05517.x
- Issue published online: 21 AUG 2013
- Article first published online: 22 FEB 2013
Background Patients with psoriasis experience a higher risk of cardiovascular and metabolic comorbidities and have a high burden of treatment. There is still a gap between treatment options and quality of care. The purpose of this study was to determine the demographic data, comorbidities, and the limitations of quality of life in patients with plaque-type psoriasis.
Materials and methods This epidemiological evaluation was designed as a single-center, cross-sectional, prospective study in Marburg, Germany. To investigate the association between mild to severe psoriasis and comorbidities, data were obtained from 133 patients.
Results The average Psoriasis Area and Severity Index was 13.4, and the average Dermatology Life Quality Index was 6.3. Among the patients with severe psoriasis, 95% had been prescribed systemic treatments. Comorbidities were evaluated, with depression 30.8%, arterial hypertension 39.1%, and hypercholesterolemia 20.3% in all patients.
Conclusions Our findings underscore the importance of cardiovascular and metabolic risk screening for all patients with psoriasis. There is still a need for systemic treatments and the definition of treatment goals for psoriasis as a systemic inflammatory disease. Such goals should integrate parameters that include comorbidities and an improvement in health-related quality of life.